Assessment of Some Biochemical Markers (Protein Levels, Hepatic Enzymes, Calcium, and Iron) Status in Patients of Diabetic Nephropathy in Thi-Qar/ Iraq
DOI:
https://doi.org/10.32792/utq/utjsci/v12i2.1385Abstract
Diabetic nephropathy is a kidney disease that develops as a complication of diabetes, and it is issociated with renal impairment with increasing age. Renal impairment among diabetic individuals can be detected using serum markers of glomerular filtration rate and microalbuminuria. This study was carried out at AL-Hussein Hospital and Consulting Laboratories .The study period extended from October 2024 to January 2025. aiming to assess the biochemical changes in kidney failure patients with and without diabetes. Based on the results, it was noted that diabetic patients had higher levels of total protein and lower levels of albumin compared to the healthy control group. Additionally, patients with diabetic nephropathy had elevated levels of liver enzymes (ALT, AST, and ALP), C-reactive protein (CRP) ,and calcium. A noticeable lower iron levels were observed in both diabetic and diabetic nephropathy groups compared to the healthy control group.
Received: 2025-04-30
Revised: 2025-06-22
Accepted: 2025-07-09
References
[1] L. A. Lilia, N. Prakoura, A. Michon, R. Chalghoumi, S. R. Wurm, M. C. Banas, and C. Chatziantoniou, "Role of periostin and nuclear factor-κB interplay in the development of diabetic nephropathy," Cells, vol. 11, no. 14, p. 2212, 2022. doi: 10.3390/cells11142212.
[2] K. V. Vishnupriya, "Evaluation of anti-diabetic activity of ethanolic extract of leaves of Pouteria campechiana (Kunth)," Ph.D. dissertation, Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, 2019.
[3] J. M. Narjes and A. S. Abdul-Razaq, "Evaluation of biomarkers in Iraqi patients with diabetes mellitus type 2," Egypt. J. Hosp. Med., vol. 90, no. 2, pp. 3062–3066, 2023. doi: 10.21608/ejhm.2023.291182.
[4] P. N. Minh and K. Eggleston, "Diabetes prevalence and risk factors among Vietnamese adults: Findings from community-based screening programs," Diabetes Care, vol. 38, no. 5, pp. e77–e78, 2015. doi: 10.2337/dc14-2506.
[5] K. A. M. Al Bermani and F. M. Abdul Adheem, "Chronic diabetes type 2; screening for chronic kidney disease in a sample of Iraqi patients," JMSP, vol. 9, no. 4, pp. 178–186, 2023.
[6] U. L. Mark and R. Hess, "Assessment of health-related quality of life among patients with chronic kidney disease," Adv. Chronic Kidney Dis., vol. 14, no. 4, pp. 345–352, 2007. doi: 10.1053/j.ackd.2007.07.009.
[7] H. R. Hazem and S. J. Abdulrahman, "Assessment the role of kidney function and total proteins in patients with diabetic nephropathy in Kirkuk City/Iraq," J. Prev. Diagn. Manag. Hum. Dis., vol. 4, no. 1, pp. 13–21, 2024.
[8] R. Sana, A. Sattar, A. Khalid, and S. Rafaqat, "Role of liver parameters in diabetes mellitus—A narrative review," Endocr. Regul., vol. 57, no. 1, pp. 200–208, 2023. doi: 10.2478/enr-2023-0022.
[9] C. Aditya, N. Mehra, M. Misra, R. Jatale, and S. Ramchandran, "Liver function test and diabetes mellitus: Correlation from a laboratory perspective," Indian J. Med. Biochem., vol. 27, no. 2, pp. 40–44, 2023.
[10] S. Juan et al., "C-reactive protein: An in-depth look into structure, function, and regulation," Int. Sch. Res. Notices, vol. 2014, p. 653045, 2014. doi: 10.1155/2014/653045
[11] A. R. J. Manuel, D. McClain, and M. Manco, "Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes," Diabetes Care, vol. 38, no. 11, pp. 2169–2176, 2015. doi: 10.2337/dc15-0605.
[12] L. S. Andrew and L. A. Stevens, "Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions," Am. J. Kidney Dis., vol. 55, no. 4, pp. 622–627, 2010. doi: 10.1053/j.ajkd.2010.02.337.
[13] N. Vikrant, N. Sharma, R. Sharma, Y. S. Rajput, and B. Mann, "Applicability of protein estimation methods for assaying glycomacropeptide," Int. J. Dairy Technol., vol. 71, no. 2, pp. 539–543, 2018. doi: 10.1111/1471-0307.12468.
[14] A. Z. A. Ekheiwsh, "Determination the levels of C-reactive protein in rheumatoid arthritis patients in Babylon Province/Iraq," Al-Qadisiyah Med. J., vol. 5, no. 8, pp. 17–22, 2009.
[15] K. H. M. Al-Rawi, Introduction to Statistics, 2nd ed. Mosul, Iraq: University of Mosul, College of Agriculture and Forestry, 2000.
[16] R. Amir, S. Zamir, A. Bhatti, S. S. Jan, and S. Ali, "Evaluation of albuminuria, total plasma proteins, and serum albumin in diabetics," Gomal J. Med. Sci., vol. 10, no. 2, 2012.
[17] A. A. Nazki, A. Syyeda, and S. Mohammed, "Total proteins, albumin and HbA1c in type 2 diabetes mellitus," Medpulse Int. J. Biochem., vol. 3, no. 3, pp. 40–42, 2017.
[18] A. S. Pallavi et al., "Spuriously high prevalence of prediabetes diagnosed by HbA1c in young Indians partly explained by hematological factors and iron deficiency anemia," Diabetes Care, vol. 35, no. 4, pp. 797–802, 2012. doi: 10.2337/dc11-1321.
[19] G. M. Amruta, A. Chen, and A. M. Vuong, "Associations between neonicotinoids and liver function measures in US adults: National Health and Nutrition Examination Survey 2015–2016," Environ. Epidemiol., vol. 8, no. 3, p. e310, 2022. doi: 10.1097/EE9.0000000000000310.
[20] G. Yana et al., "How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?," Hepatol. Int., vol. 15, pp. 21–35, 2021. doi: 10.1007/s12072-020-10121-2.
[21] K. M. Ammar et al., "Abnormal liver enzymes: A review for clinicians," World J. Hepatol., vol. 13, no. 11, p. 1688, 2021. doi: 10.4254/wjh.v13.i11.1688.
[22] B. Yaru et al., "Clinical evidence of the relationship between alanine aminotransferase and diabetic kidney disease," Diabetes Metab. Syndr. Obes., vol. 17, pp. 261–269, 2024. doi: 10.2147/DMSO.S452513.
[23] F. O. Layla, "Study of partially purification AST activity in sera of Iraqi patients with diabetic nephropathy," Atherosclerosis, vol. 14, no. 9, p. 12, 2014.
[24] K. S. Abdullah et al., "Aflatoxin B1 as a threshold concept of uncertain etiology of chronic kidney diseases," Indian J. Forensic Med. Toxicol., vol. 15, no. 3, 2021.
[25] M. Secil, S. Cenesiz, and M. Yarim, "Determination of the effect of quercetin on oxidant-antioxidant parameters in the blood and liver tissues of rats given sodium fluoride experimentally," J. Indian Chem. Soc., vol. 99, no. 7, p. 100486, 2022. doi: 10.1016/j.jics.2022.100486.
[26] C. Hui et al., "The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients," Diabetes Res. Clin. Pract., vol. 100, no. 2, pp. 272–276, 2013. doi: 10.1016/j.diabres.2013.03.007.
[27] Z. Lijun et al., "Association between serum alkaline phosphatase and renal outcome in patients with type 2 diabetes mellitus," Ren. Fail., vol. 42, no. 1, pp. 818–828, 2020. doi: 10.1080/0886022X.2020.1805466.
[28] Q. Hanrui et al., "Combined toxicity evaluation of ochratoxin A and aflatoxin B1 on kidney and liver injury, immune inflammation, and gut microbiota alteration through pair-feeding pullet model," Front. Immunol., vol. 13, p. 920147, 2022. doi: 10.3389/fimmu.2022.920147.
[29] W. Agata and K. Balawender, "Structural and metabolic changes in bone," Animals, vol. 12, no. 15, p. 1946, 2022. doi: 10.3390/ani12151946.
[30] A. Yasuaki et al., "Serum high-sensitivity C-reactive protein levels are associated with high risk of development, not progression, of diabetic nephropathy among Japanese type 2 diabetic patients: A prospective cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT7])," Diabetes Care, vol. 37, no. 11, pp. 2947–2952, 2014. doi: 10.2337/dc14-0714.
[31] Z. S. Akreem, E. R. Sarhat, and S. J. Khalaf, "Association of C-reactive protein with risk of complications of diabetic nephropathy," Egypt. J. Chem., vol. 65, no. 8, pp. 483–487, 2022. doi: 10.21608/ejchem.2022.118048.5365.
[32] Y. Y. Ke et al., "C-reactive protein promotes diabetic kidney disease in db/db mice via the CD32b-Smad3-mTOR signaling pathway," Sci. Rep., vol. 6, p. 26740, 2016. doi: 10.1038/srep26740.
[33] S. T. Ashraf, V. D. Sanctis, M. Yassin, and N. Soliman, "Iron deficiency anemia and glucose metabolism," Acta Biomed., vol. 88, no. 1, p. 112, 2017.
[34] R. N. Roberto et al., "Iron deficiency in chronic kidney disease patients with diabetes mellitus," Diabetes Metab. Syndr. Clin. Res. Rev., vol. 12, no. 6, pp. 933–937, 2018. doi: 10.1016/j.dsx.2018.05.020.
[35] G. G. Anat, A. Schechter, and B. R. Zvi, "Iron deficiency anemia in chronic kidney disease," Acta Haematol., vol. 142, no. 1, pp. 44–50, 2019. doi: 10.1159/000496492.
[36] A. S. Cathrine et al., "On iron metabolism and its regulation," Int. J. Mol. Sci., vol. 22, no. 9, p. 4591, 2021. doi: 10.3390/ijms22094591.
[37] M. Wojciechowska, O. W. Wisniewski, P. Kolodziejski, and H. Krauss, "Role of hepcidin in physiology and pathophysiology. Emerging experimental and clinical evidence," J. Physiol. Pharmacol., vol. 72, no. 1, 2021.
[38] A. H. O. Dakhil, "Relationships between iron, oxidative stress, glycated proteins and the development of atherosclerosis in Type 2 diabetes," Ph.D. dissertation, University of Leicester, 2015.
[39] S. Singh and S. Bhatta, "Biochemical and hematological parameters in chronic kidney disease," J. Manmohan Mem. Inst. Health Sci., vol. 4, no. 1, pp. 4–11, 2018.
[40] M. M. Ahmed et al., "Study of the changes of some biochemical parameters of patients with renal failure," Bull. Natl. Inst. Health Sci., vol. 140, no. 3, pp. 2925–2933, 2022.
[41] H. M. Ramy et al., "Calcium transport in the kidney and disease processes," Front. Endocrinol., vol. 12, p. 762130, 2022. doi: 10.3389/fendo.2021.762130.
[42] D. A. Lima, H. Dimke, and R. T. Alexander, "Biology of calcium homeostasis regulation in intestine and kidney," Nephrol. Dial. Transplant., vol. 40, no. 3, pp. 435–445, 2025.
[43] R. S. Alluru, "Calcium, phosphorus, and magnesium disorders and kidney stones," in Absolute Nephrology Review: An Essential Q & A Study Guide. Cham, Switzerland: Springer, 2022, pp. 173–209.
[44] T. Tamara, N. J. Piqueras, and S. M. Geisler, "Role of high voltage-gated Ca2+ channel subunits in pancreatic β-cell insulin release. From structure to function," Cells, vol. 10, no. 8, p. 2004, 2021. doi: 10.3390/cells10082004.
Downloads
Published
License
Copyright (c) 2025 University of Thi-Qar Journal of Science
This work is licensed under a Creative Commons Attribution 4.0 International License.
